The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | The importance of raising awareness and early diagnosis in amyloidosis
Scarlett McNally, BSc, MB, BChir, FRCS(Tr&Orth), MA, MBA, FAcadMed, East Sussex Healthcare NHS Trust, Sussex, UK, discusses the importance of early diagnosis in amyloidosis from a patient perspective. Dr McNally explains that raising awareness of amyloidosis and improving technologies are allowing patients to be diagnosed earlier, which results in improved outcomes for patients. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
